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1 
Goal of the Study 
Qualitative analysis of thirty 
(30) marker components from 
fifteen (15) serum samples 




• Liver fibrosis is a reversible wound-healing response to cellular injury with the 
characteristics of the excessive accumulation of extracellular matrix (ECM) 
proteins including collagen that occurs in most types of chronic liver diseases.  
• Fuzheng Huayu (FZHY) is a China Food and Drug Administration (CFDA) 
approved Traditional Chinese Medicines (TCM) product for the treatment of 
liver fibrosis in 2002. Its phase II clinical trial in the US had completed in 2013.  
• FZHY is composed of six Chinese medicinal herbs and effective for treatment of 
liver fibrosis causing by chronic hepatitis B.  
• The pharmacokinetics features of FZHY and bio-marker(s) to affect the 
pathological state of liver fibrosis are still not clear or well addressed. 
• Systemically analyze the samples from phase II clinical trial will help to 
understand the absorption of FZHY in human body and to identify the key 
metabolites of FZHY. 
3 
Formula of FZHY 
T. Yang, S. Liu, et al.,  J. Ethnopharm.  2015, 166: 305-312 
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Major Marker Compounds in Danshen (Salvia miltiorrhizea Bge) 
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Major Marker Compounds in Wuweizi (Schisandrae chinensis) 
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Major Marker Compounds in Jiaogulan (Gynostemma pentaphyllum) 
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Acquity UPLCTM HSS 
T3 column 
Mobile Phase 
Acetonitrile and Water 
with 0.1% formic acid 
Temperature 45 ºC 




ESI Positive and 
Negative 
Source temp. 150C  
Desolvation 
temp. 
300 C  
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Salvianolic acid B 
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Group A Group B 
A1 A41131604 Collected on 10/21/11 B1 A34704904 Collected on 02/22/11 
A2 A43732106 Collected on 12/19/11 B2 A41883706 Collected on 03/24/11 
A3 A43764806 Collected on 01/19/12 B3 A41884506 Collected on 04/19/11 
A4 A44740206 Collected on 03/13/12 B4 A34707506 Collected on 06/07/11 
A5 A44741406 Collected on 06/04/12 B5 A43763406 Collected on 09/15/11 
A6 A44832006 Collected on 08/31/12 B6 A43732906 Collected on 02/29/12 
A7 A44514904 Collected on 11/06/12     
A8 A44515701 Collected on 11/19/12     
A9 A44831606 Collected on 02/12/13     
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Typical Chromatograms of Marker Compounds Detected on LC-MS/MS 







Total 15 serum samples (Group A: 9 samples; Group B: 6 samples) were analyzed. 
The results showed that schisandrol A, schisandrol B, schisandrin A, schisandrin B, 
schisantherin A, and ombuin were found in some of Group A samples, but not 
detected from Group B samples. Adenosine and guanosine were identified in all 
serum samples. Apart from this, other 22 marker compounds (see Results part) 
were not detected from any of serum samples.  
  
In conclusion, marker compounds schisandrol A, schisandrol B, schisandrin A, 
schisandrin B, schisantherin A, and ombuin were identified in serum samples 
collected from a patient in FZHY Phase II study.  
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